20.500.12556/DKUM-86401 The multi-strain probiotic OMNi-BiOTiC® Active reduces the duration of acute upper respiratory disease in older people a double-blind, randomised, controlled clinical trial Immunosenescence is the adverse change in the human immune function during aging, leaving older people more prone to an increased risk of infections and morbidity. Acute upper respiratory tract infections (URTIs) are very common among older people, often resulting in continued morbidity and mortality. Therefore, approaches, such as consuming probiotics, that shorten the duration or even reduce the incidence of URTIs in older people are being studied. The aim of this study was to determine the effects of a multi-strain probiotic OMNi-BiOTiC® Active, which contains 11 live probiotic strains, on the incidence, duration, and severity of URTIs in older people. In this randomized double-blinded placebo-controlled study, 95 participants, with an average age of 70.9 years in the probiotic group and 69.6 years in the placebo group, were randomly allocated to two groups: 1010 cfu per day of the multi-strain probiotic intervention OMNi-BiOTiC® Active (49) or placebo (46). The incidence of URTIs in older people after 12 weeks supplementation with OMNi-BiOTiC® showed no statistically significant difference between the two groups (p = 0.5244). However, the duration of the URTI infections was statistically significantly different between the groups (p = 0.011). The participants that consumed the probiotic had an average duration of illness of 3.1 ± 1.6 days, whilst participants that received the placebo had symptoms for an average of 6.0 ± 3.8 days (p = 0.011). Statistically significant differences in lymphocyte counts in both groups after supplementation (p = 0.035 for the probiotic group and p = 0.029 for the placebo group) and between both groups were found (p = 0.009). Statistically significant differences in eosinophil (p = 0.002) and basophil counts (p = 0.001) in the probiotic groups before and after supplementation with probiotics were also found. Supplementation with the multi-strain probiotic OMNi-BiOTiC® Active may benefit older people with URTIs. Larger randomised controlled clinical trials are warranted. Clinical Trial Registration; identifier NCT05879393. upper respiratory tract infection URTI duration of illness probiotics multi-strain older people immune function true true true Angleški jezik Angleški jezik Članek v reviji 2023-11-27 13:48:13 2023-11-27 14:13:00 2023-11-28 03:08:54 0000-00-00 00:00:00 2023 0 0 Str. 1-13 iss. 7, [article no.] 1760 Vol. 11 2023 0000-00-00 PostprintKoncna Objavljeno apc 0000-00-00 0000-00-00 2023-01-01 613.292:616.21-053.9 158306563 10.3390/microorganisms11071760 2076-2607 ProURTI-RCT-fijan.pdf ProURTI-RCT-fijan.pdf 1 BEB539B60231CF917E6FB7AD957F01AB 45e2d290ee6619613afbaa2d87b85fe1101b26198a287d07c500a242d2191b08 4c628ca9-8d23-11ee-88ec-00155d000105 https://dk.um.si/Dokument.php?lang=slv&id=174337 Fakulteta za zdravstvene vede 0 0 0